CMMB
Chemomab Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.71
−4.24%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
Market Cap
$19.86M
MomentumView details →
1D Return
−4.24%
YTD Return
+78.23%
RSI (14)
87.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
Market Cap
$19.86M
RSI (14)
87.1
MomentumView details →
1D Return
−4.24%
YTD Return
+78.23%
SummaryUpdated Jun 1, 2026
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) is a clinical-stage biotechnology company founded in 2011 and headquartered in Tel Aviv, Israel. The company went public in February 2019 and was formerly known as Anchiano Therapeutics Ltd. before changing its name to Chemomab Therapeutics in March 2021. Chemomab focuses on developing innovative therapeutics for the treatment of inflammation and fibrosis, conditions that affect millions of patients worldwide and represent significant unmet medical needs.
Similar companies
Latest newsMore news →